List of Excipients in Branded Drug PREDNISOLONE ACETATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
A-S Medication Solutions	PREDNISOLONE ACETATE	prednisolone acetate	50090-0559	BENZALKONIUM CHLORIDE
A-S Medication Solutions	PREDNISOLONE ACETATE	prednisolone acetate	50090-0559	CITRIC ACID MONOHYDRATE
A-S Medication Solutions	PREDNISOLONE ACETATE	prednisolone acetate	50090-0559	EDETATE DISODIUM
A-S Medication Solutions	PREDNISOLONE ACETATE	prednisolone acetate	50090-0559	GLYCERIN

Generic Drugs Containing PREDNISOLONE ACETATE

Company	Ingredient	NDC	Excipient
A-S Medication Solutions	prednisolone acetate	50090-7539	BENZALKONIUM CHLORIDE
A-S Medication Solutions	prednisolone acetate	50090-7539	BORIC ACID
A-S Medication Solutions	prednisolone acetate	50090-7539	EDETATE DISODIUM
A-S Medication Solutions	prednisolone acetate	50090-7539	HYPROMELLOSE 2906

What are the Most Frequently-Used Excipients in PREDNISOLONE ACETATE?

# Of NDCs	Excipient
4	BENZALKONIUM CHLORIDE
4	BORIC ACID
4	EDETATE DISODIUM
1	HYPROMELLOSE

Prednisolone Acetate Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Prednisolone acetate is a mature ophthalmic corticosteroid with limited active-ingredient differentiation and substantial opportunity in formulation performance, preservative systems, manufacturing efficiency, and market access. The main commercial product is a sterile ophthalmic suspension, typically at 1% strength. Generic competition is established, original composition patents are no longer the principal barrier, and no biosimilar pathway applies. Commercial value is concentrated in physical stability, dose uniformity, patient tolerability, packaging, and differentiated delivery formats.

What products contain prednisolone acetate?

Prednisolone acetate is marketed mainly as a topical ophthalmic suspension for steroid-responsive inflammatory conditions of the eye. The leading reference product is Pred Forte, a 1% ophthalmic suspension historically associated with Allergan, now within AbbVie’s product portfolio. Other marketed presentations include lower-strength prednisolone acetate suspensions, including 0.12% products in some markets.

Product characteristic	Typical market position
Active ingredient	Prednisolone acetate
Dosage form	Sterile ophthalmic suspension
Common strength	1%
Lower strength	0.12% in selected products
Therapeutic class	Ophthalmic corticosteroid
Primary use	Steroid-responsive ocular inflammation
Administration	Topical ocular instillation
Regulatory pathway	NDA reference product; ANDA generic products
Biosimilar relevance	None; prednisolone acetate is a synthetic small molecule
Key formulation issue	Uniform resuspension and dose delivery

The drug is poorly suited to a conventional clear aqueous solution because prednisolone acetate has low water solubility. Suspension technology is therefore central to product performance.

Which excipients are used in prednisolone acetate ophthalmic suspensions?

Commercial prednisolone acetate suspensions commonly use a combination of wetting agents, buffering agents, tonicity modifiers, chelators, preservatives, and viscosity-control components. The exact composition differs by manufacturer and product strength.

Excipient category	Representative excipients	Primary function
Wetting and dispersion	Polysorbate 80	Improves wetting and dispersion of hydrophobic drug particles
Buffering	Boric acid, sodium citrate	Controls pH and supports chemical stability
Tonicity adjustment	Sodium chloride, boric acid	Improves ocular tolerability
Chelation	Edetate disodium	Binds trace metals and may improve preservative performance
Preservation	Benzalkonium chloride or other approved preservative systems	Controls microbial growth in multidose containers
Vehicle	Purified water	Continuous phase
pH adjustment	Sodium hydroxide or hydrochloric acid	Sets final product pH
Viscosity control	Cellulosic polymers or other rheology modifiers	Extends ocular residence time and limits sedimentation
Packaging support	Low-binding container and closure materials	Limits adsorption, extractables, and dose loss

Pred Forte labeling identifies excipients including boric acid, sodium citrate, sodium chloride, edetate disodium, polysorbate 80, and purified water, with pH adjustment as required. The product is supplied as a sterile suspension and requires shaking before use. [1]

Generic products may use different preservative concentrations, surfactants, viscosity modifiers, or buffering systems. Those differences can affect particle-size distribution, sedimentation rate, redispersibility, drop size, ocular sensation, and storage stability.

How should an excipient strategy be designed for prednisolone acetate?

The formulation objective is not simply to suspend the drug. A commercially competitive product must provide consistent drug delivery throughout the bottle, rapid redispersion after storage, acceptable comfort, and microbiological protection.

Control particle size and crystal morphology

Prednisolone acetate particle size has a direct effect on suspension stability, dose uniformity, ocular residence, and irritation. Smaller particles can improve uniformity but may increase surface energy, aggregation, and manufacturing complexity. Larger particles may sediment rapidly and create variable dosing.

A development program should control:

• Median particle size and distribution width
• Crystal habit and polymorphic form
• Aggregation after sterilization or storage
• Sedimentation volume
• Redispersibility after defined shaking conditions
• Delivered dose at the beginning, middle, and end of container use

Particle engineering is one of the strongest opportunities for product differentiation because it can be protected through manufacturing know-how, process patents, or formulation claims.

Select the surfactant system carefully

Polysorbate 80 is widely used to wet hydrophobic corticosteroid particles. Its concentration must be balanced against ocular tolerability, oxidative degradation, foaming, and interaction with packaging materials.

Potential development alternatives include:

• Poloxamers
• Tyloxapol
• Nonionic surfactant combinations
• Phospholipid-based wetting systems
• Surface-modified drug particles

A replacement or reduced-surfactant formulation may appeal to preservative-sensitive or irritation-sensitive patients, provided that the alternative system maintains sterility, uniformity, and shelf life.

Optimize suspension rheology

Sedimentation can be reduced through controlled viscosity, but excessive viscosity may impair drop formation, blur vision, or create poor patient acceptance. Rheology should be assessed under conditions relevant to the eye-drop bottle rather than only under laboratory shear conditions.

Commercially relevant targets include:

• Minimal hard-cake formation
• Rapid redispersion
• Consistent drop volume
• Low residual volume in the bottle
• Limited transient visual blur
• Compatibility with conventional multidose droppers

A structured rheology system may support a meaningful product claim if it improves dose uniformity without increasing administration burden.

What formulations are protected or commercially differentiated?

Prednisolone acetate formulation opportunities fall into five main categories.

Preservative-reduced or preservative-free products

Benzalkonium chloride is widely used in multidose ophthalmic products but can contribute to ocular-surface irritation, particularly with repeated dosing or compromised corneal barriers. A preservative-free prednisolone acetate suspension could target postoperative patients, chronic inflammatory conditions, and patients with ocular-surface disease.

The main technical barrier is multidose sterility. Commercial solutions may include:

• Unit-dose containers
• Multidose preservative-free valves
• Filtered dispensing systems
• One-way closure systems
• Low-bioburden manufacturing and filling processes

The opportunity is strongest where the product can command a premium or gain formulary preference despite higher packaging cost.

Improved redispersibility

A suspension that redisperses with fewer shakes can improve dose consistency and reduce administration errors. This may be supported by:

• Narrower particle-size distributions
• Controlled crystal morphology
• Polymer-assisted stabilization
• Optimized density matching
• Low-energy sedimentation systems
• Structured vehicle design

The development target should be measurable, such as redispersion after a defined storage interval with a defined number of inversions.

Reduced blur and improved comfort

Prednisolone acetate suspensions can temporarily affect visual clarity because of suspended particles and vehicle properties. Lower particle size, improved dispersion, lower viscosity, and optimized drop volume may reduce this effect.

Comfort-related differentiation is commercially relevant in postoperative care, where patients may already be using multiple ocular products.

Extended residence time

Mucoadhesive or in situ gelling systems can increase ocular residence time and potentially reduce dosing frequency. Candidate excipients include selected cellulose derivatives, carbomers, hyaluronic acid, and thermoresponsive polymers.

These systems create regulatory and clinical complexity. Increasing residence time can also increase local steroid exposure and adverse-effect risk. A successful product must demonstrate a clinically meaningful benefit rather than only higher viscosity.

Alternative delivery systems

Prednisolone acetate may be incorporated into:

• Unit-dose suspension vials
• Multidose preservative-free containers
• Drug-loaded ocular inserts
• Injectable or implantable postoperative systems
• Combination products with antibiotics
• Sustained-release ocular delivery devices

Alternative delivery systems can create stronger IP positions than a conventional generic suspension, although they require more extensive clinical and device development.

What is the FDA regulatory status of prednisolone acetate?

Prednisolone acetate ophthalmic suspension is an established FDA-regulated drug product. The reference product was approved through the NDA pathway, while subsequent manufacturers generally rely on ANDA approval.

The key regulatory requirements include:

• Sterility
• Assay and impurity control
• Particle-size distribution
• Uniformity of delivered dose
• Resuspendability
• Preservative effectiveness, where applicable
• Container-closure integrity
• Stability throughout the labeled shelf life
• Compatibility with the dropper and bottle
• Appropriate ophthalmic labeling

For a conventional generic suspension, demonstrating pharmaceutical equivalence and bioequivalence can be more complex than for a simple aqueous solution. FDA review may focus closely on particle size, polymorphism, viscosity, rheology, drop size, and comparative performance.

What is the Orange Book status of prednisolone acetate?

Prednisolone acetate ophthalmic products are listed in FDA drug databases and the Orange Book through reference-listed products and approved generic products. The original product’s regulatory exclusivity and core composition patent protection expired long ago. Current commercial competition is therefore based primarily on abbreviated approvals, manufacturing capability, supply reliability, branding, and product differentiation.

For any specific ANDA, Orange Book patent certification and listing status must be assessed at the product level. A generic applicant may confront:

• Listed method-of-use patents, if any remain relevant
• Product-specific formulation patents
• Device or container patents
• Manufacturing process claims
• State-law or commercial litigation unrelated to core drug exclusivity

The mature status of the molecule means that an applicant should not assume that absence of a major active-ingredient patent eliminates all launch risk.

When did prednisolone acetate lose exclusivity?

The original prednisolone acetate ophthalmic product lost meaningful market exclusivity decades ago. Generic entry is established, and multiple manufacturers have marketed products in the United States.

The commercial exclusivity profile is summarized below.

Exclusivity category	Current relevance
New chemical entity exclusivity	Expired
Original product patent protection	Expired or commercially immaterial
Pediatric exclusivity	No principal current barrier identified
Orphan exclusivity	Not applicable
Biosimilar exclusivity	Not applicable
Generic competition	Established
Formulation-specific protection	Potentially relevant for new products
Device protection	Potentially relevant for differentiated packaging

The main remaining opportunity is not recovery of exclusivity on the old active ingredient. It is the creation of a differentiated product with new formulation, delivery, packaging, or clinical-use claims.

What patent strategies are available for prednisolone acetate?

A new entrant should focus its IP program on formulation and process claims rather than broad composition-of-matter claims.

Formulation patents

Potential claim areas include:

• Defined particle-size distributions
• Specific polymorphic or crystalline forms
• Surfactant and buffer combinations
• Preservative-free multidose systems
• Viscosity and rheology ranges
• Improved redispersibility
• Reduced settling or caking
• Controlled drop size
• Extended ocular residence
• Combination suspensions

Method-of-use patents

Potential indications include postoperative inflammation, uveitis, ocular-surface inflammation, or steroid-responsive conditions. Method-of-use claims are exposed to labeling constraints and may be difficult to enforce against off-label use.

Manufacturing patents

Manufacturing claims may cover:

• Wet milling or high-pressure homogenization
• Controlled crystallization
• Sterile processing
• Aseptic filling
• Particle-size control
• Surface modification
• Drug-excipient premixing
• Suspension concentration and deagglomeration

Process patents can protect a product even when the final formulation appears similar to older products, but infringement detection may be difficult.

Are there Paragraph IV challenges involving prednisolone acetate?

Paragraph IV challenges are most relevant when an ANDA applicant certifies that a listed patent is invalid, unenforceable, or not infringed. Prednisolone acetate’s core products are mature, so the main Paragraph IV exposure would arise from later-listed formulation, method-of-use, or delivery-system patents rather than the original active ingredient.

The business implications are:

• Conventional 1% suspension products face mature generic competition.
• A newly patented preservative-free or extended-residence product could generate Paragraph IV risk.
• A generic applicant may pursue a non-infringing formulation design.
• Litigation risk depends on the scope and expiration of any product-specific patents listed for the reference product.

No general biosimilar challenge framework applies because prednisolone acetate is a small molecule, not a biologic.

Which companies compete in prednisolone acetate?

Competition includes the reference-product owner, large generic manufacturers, ophthalmic specialty companies, and regional manufacturers.

The competitive factors are:

Factor	Commercial effect
Low manufacturing cost	Supports generic price competition
Sterile ophthalmic capability	Limits the qualified supplier base
Reliable raw-material supply	Reduces shortage and substitution risk
Formulation quality	Affects complaints and physician preference
Preservative-free packaging	Supports premium positioning
Hospital and pharmacy contracting	Determines volume access
Brand recognition	Supports continued reference-product sales
Combination products	Increases prescribing convenience

Companies with sterile ophthalmic manufacturing, validated suspension processes, and proprietary dispensing systems have a stronger platform for differentiated products than manufacturers relying solely on commodity generic production.

What commercial opportunities exist?

The most credible opportunities are premium generics and specialty ophthalmic products.

Premium generic suspension

A premium generic could target:

• Better redispersibility
• Lower shake burden
• More consistent dose delivery
• Reduced ocular irritation
• Improved drop-size control
• Extended shelf life
• More user-friendly packaging

The product would need a clear benefit over low-cost generics to support pricing.

Preservative-free product

A preservative-free formulation is the strongest obvious differentiation route. Unit-dose packaging is technically straightforward but increases material, filling, and distribution costs. Multidose preservative-free technology offers greater convenience and margin potential but requires more complex device development.

Combination product

Prednisolone acetate may be paired with an ophthalmic antibiotic for postoperative use. Combination products can improve adherence and reduce the number of bottles, but they face additional formulation compatibility, antimicrobial, resistance, and clinical-development requirements.

Contract development and manufacturing

Sterile suspension development is a service opportunity. Companies with particle-engineering, aseptic filling, and ophthalmic packaging capabilities can license platform technology or offer contract development services to regional pharmaceutical manufacturers.

Emerging-market supply

Many markets remain price-sensitive but have inconsistent availability of ophthalmic steroids. A manufacturer with regulatory registrations, reliable supply, and competitive packaging can expand through branded generics without requiring novel active-ingredient IP.

How strong is the patent estate for prednisolone acetate?

The legacy patent estate is weak as a barrier to conventional generic entry. The stronger protection opportunities relate to new delivery formats and measurable formulation performance.

IP category	Strength for conventional 1% suspension	Strength for differentiated product
Active ingredient	Low	Low
Original composition	Low	Low
Particle engineering	Moderate	High
Preservative-free packaging	Low to moderate	High
Extended-release delivery	Low	High
Method of use	Low to moderate	Moderate
Manufacturing process	Moderate	Moderate to high
Device and container	Low	Moderate to high
Trade secrets	Moderate	High

Trade secrets may be more valuable than patents for particle processing, aseptic filling parameters, suspension conditioning, and packaging-line controls.

What generic launch scenarios exist?

A generic or follow-on applicant has four practical launch paths.

1. A standard 1% ophthalmic suspension competing primarily on price and supply reliability.
2. A quality-differentiated suspension with improved redispersion and dose uniformity.
3. A preservative-free product using unit-dose or multidose technology.
4. A combination or extended-residence product positioned for postoperative or specialty ophthalmology.

The first path has the lowest development risk but the weakest margin profile. The third and fourth paths require more regulatory and device investment but offer stronger differentiation and IP potential.

What revenue exposure does prednisolone acetate create?

Prednisolone acetate is a mature product, so revenue exposure is generally linked to volume, manufacturing cost, and portfolio role rather than exclusivity. The reference product may retain value through brand prescribing, institutional contracts, and physician familiarity, but generic substitution limits pricing power.

Revenue risk is highest for products dependent on:

• A single sterile manufacturing site
• A single active pharmaceutical ingredient supplier
• Preservative or surfactant availability
• A specialized bottle or closure
• A narrow customer base
• A premium price without measurable clinical benefit

Revenue upside is strongest when a company controls a differentiated preservative-free device, a superior suspension platform, or a branded generic with broad geographic registrations.

Key Takeaways

• Prednisolone acetate is a mature small-molecule ophthalmic corticosteroid with established generic competition.
• The principal dosage form is a sterile ophthalmic suspension, commonly at 1% strength.
• Key excipients include wetting agents, buffers, tonicity modifiers, chelators, preservatives, and viscosity-control polymers.
• Particle size, redispersibility, sedimentation, drop size, and preservative tolerance are the central formulation variables.
• The original active-ingredient and product exclusivity barriers have expired.
• Biosimilar risk does not apply; generic and follow-on product competition does.
• The strongest commercial opportunities are preservative-free delivery, improved suspension performance, differentiated packaging, combination products, and specialty ophthalmic manufacturing.
• The strongest new IP positions are likely to come from particle engineering, delivery systems, manufacturing processes, and measurable performance claims.
• Conventional 1% generic entry is commercially accessible but likely to produce limited margins without supply, quality, or branding advantages.

FAQs About Prednisolone Acetate Excipients and Commercial Strategy

Can prednisolone acetate ophthalmic suspension be formulated without benzalkonium chloride?

Yes. A preservative-free product can use unit-dose packaging or a validated multidose preservative-free dispensing system. The formulation must maintain sterility through the labeled in-use period.

Which excipient most directly improves prednisolone acetate suspension stability?

The answer depends on the failure mode. Polysorbate 80 improves wetting, while viscosity modifiers and structured vehicles can reduce sedimentation. Particle engineering often has the largest effect on long-term redispersibility.

Is prednisolone acetate suitable for an extended-release eye drop?

Yes, in principle. Polymer-based vehicles, in situ gels, inserts, and drug-loaded devices can extend residence time. The main development issues are dose control, comfort, visual blur, and steroid exposure.

Can a new prednisolone acetate product obtain patents despite expired original protection?

Yes. New patents may cover particle size, crystalline form, excipient ratios, preservative-free packaging, delivery devices, manufacturing processes, or specific therapeutic uses. Broad claims covering the old suspension are unlikely to provide the same protection as the original product claims.

What is the most attractive commercial differentiation for a new entrant?

A preservative-free multidose product with reliable resuspension and consistent drop delivery offers the clearest premium opportunity. It combines a patient-relevant benefit with potential formulation, device, and manufacturing IP.

References

1. AbbVie Inc. (2023). Pred Forte (prednisolone acetate ophthalmic suspension, USP) 1% prescribing information. U.S. Food and Drug Administration labeling repository.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. FDA.

3. U.S. Food and Drug Administration. (2024). Inactive ingredient database. FDA.

4. United States Pharmacopeial Convention. (2024). USP-NF: Ophthalmic preparations and prednisolone acetate monograph. United States Pharmacopeial Convention.

5. U.S. Food and Drug Administration. (2024). Guidance for industry: ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant origin. FDA.

6. DailyMed. (2024). Prednisolone acetate ophthalmic suspension product labeling. National Library of Medicine.